Advaxis completes patient recruitment in ADXS11-001 phase II study for cervical dysplasia

Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, completes recruitment of the first group of patients in its US cervical dysplasia (CIN) phase II study of ADXS11-001 as required for the planned DMSB (safety board) meeting scheduled to be held January 11, 2011.

Following that meeting, the low dose portion of the study will complete recruitment and should be able to be reported on or about September 2011.

Advanced cervical dysplasia CIN leads to invasive cervical cancer. This trial follows from the promising findings in Advaxis' ADXS11-001 phase I clinical trial in late stage cervical cancer.